CARBOPLATIN IN PREVIOUSLY TREATED MULTIPLE-MYELOMA - A CANCER AND LEUKEMIA GROUP-B PHASE-II TRIAL

被引：2

作者：

OMURA, GA

PERRI, RT

PETERSON, B

SCHIFFER, CA

机构：

[1] UNIV ALABAMA,BIRMINGHAM,AL 35294

[2] UNIV MINNESOTA,MINNEAPOLIS,MN 55455

[3] DUKE UNIV,DURHAM,NC 27706

[4] UNIV MARYLAND,BALTIMORE,MD 21201

来源：

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 1994年 / 17卷 / 03期

关键词：

CARBOPLATIN; CHEMOTHERAPY; TOXICITY;

D O I：

10.1097/00000421-199406000-00003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Carboplatin 400 Mg/M2 per month was evaluated as a single agent in 15 patients with multiple myeloma who had had one prior chemotherapy regimen. All but three were judged to have had some degree of refractoriness to prior therapy. Hematologic toxicity was frequent and sometimes severe. There were no responses. Further evaluation of standard-dose single-agent carboplatin in refractory myeloma does not appear warranted.

引用

页码：196 / 198

页数：3

共 50 条

[21] PHASE-II TRIAL OF ACIVICIN IN ADVANCED BREAST-CARCINOMA - A CANCER AND LEUKEMIA GROUP-B STUDY
BOOTH, BW
KORZUN, AH
WEISS, RB
ELLISON, RR
BUDMAN, D
KHOJASTEH, A
WOOD, W
CANCER TREATMENT REPORTS, 1986, 70 (10): : 1247 - 1248
[22] BISANTRENE IN NON-SMALL CELL LUNG-CANCER - A PHASE-II TRIAL OF THE CANCER AND LEUKEMIA GROUP-B
GREEN, MR
VOSIKA, G
PROPERT, KJ
WARE, JH
COMIS, R
CANCER TREATMENT REPORTS, 1986, 70 (04): : 539 - 540
[23] CISPLATIN IN PATIENTS WITH GASTRIC-CANCER - A CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY
PERRY, MC
GREEN, MR
MICK, R
SCHEIN, P
CANCER TREATMENT REPORTS, 1986, 70 (03): : 415 - 416
[24] VINDESINE - A PHASE-II STUDY IN CHILDHOOD MALIGNANCIES - A REPORT FOR CANCER AND LEUKEMIA GROUP-B
ETTINGER, LJ
BRECHER, M
COLEMAN, M
SMITHSON, WA
PATTERSON, R
RUSSELL, EC
NECHELES, T
JONES, B
OHNUMA, T
MEDICAL AND PEDIATRIC ONCOLOGY, 1982, 10 (01): : 35 - 43
[25] HYPERSENSITIVITY REACTIONS TO IV MELPHALAN DURING TREATMENT OF MULTIPLE-MYELOMA - CANCER AND LEUKEMIA GROUP-B EXPERIENCE
CORNWELL, GG
PAJAK, TF
MCINTYRE, OR
CANCER TREATMENT REPORTS, 1979, 63 (03): : 399 - 403
[26] Phase II trial of menogaril in patients with previously treated multiple myeloma or chronic lymphocytic leukemia
Kucuk, O
Kilton, L
Wade, JL
Blough, R
Benson, AB
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 379 - 383
[27] PHASE-II TRIAL OF ETOPOSIDE AND CISPLATIN FOR REFRACTORY SMALL CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
GRAZIANO, SL
LEE, K
PROPERT, KJ
TINSLEY, R
HAYES, DM
GREEN, M
COMIS, RL
MEDICAL AND PEDIATRIC ONCOLOGY, 1990, 18 (01): : 22 - 26
[28] PHASE-II EVALUATION OF CHLOROZOTOCIN IN REFRACTORY MULTIPLE-MYELOMA
FORMAN, WB
COHEN, HJ
BARTOLUCCI, AA
MANNING, G
CANCER TREATMENT REPORTS, 1984, 68 (11): : 1409 - 1410
[29] A PHASE-II STUDY OF IDARUBICIN AND PREDNISONE IN MULTIPLE-MYELOMA
ALBERTS, AS
FALKSON, G
RAPOPORT, BL
UYS, A
TUMORI, 1990, 76 (05) : 465 - 466
[30] THE TREATMENT OF MELANOMA WITH M-AMSA - A CANCER AND LEUKEMIA GROUP-B PHASE-II STUDY
AMREIN, PC
POULIN, RF
COLEMAN, M
RICHARDS, F
WEIL, M
KENNEDY, BJ
CAREY, RW
GREEN, MR
HOLLAND, JF
WEINBERG, V
RAFLA, S
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1984, 7 (03): : 269 - 271

← 1 2 3 4 5 →